by CytoPrevent | Jun 17, 2020 | Studies
Christopher R. Friese, PhD, RN, AOCN®, FAAN, Mandy Wong, MS, Alex Fauer, RN, BSN, Kari Mendelsohn-Victor, MPH, Martha Polovich, PhD, RN, AOCN®, and Marjorie C. McCullagh, PhD, RN, FAAOHN, FAAN Abstract: BACKGROUND: Hazardous drug exposure is an occupational...
by CytoPrevent | Sep 18, 2019 | Studies
Antoine Villa, Mathieu Molimard, Emmanuelle Bignon, Béatrice Martinez, Magali Rouyer, Simone Mathoulin-elissier, Isabelle Baldi, Catherine Verdun-Esquer, Mireille Canal-Raffin Abstract Introduction: Antineoplastic drugs (AD) are potentially carcinogenic and/or...
by CytoPrevent | Aug 7, 2019 | Studies
Alison Simons, Samantha Toland Abstract Healthcare workers who handle or administer systemic anticancer therapy (SACT) agents are at risk of exposure to hazardous drugs known to be carcinogenic, mutagenic and teratogenic. Research suggests that there is a lack...
by CytoPrevent | Mar 23, 2019 | Studies
Christopher R. Friese, PhD, RN, AOCN, FAAN, James Yang, PhD, Kari Mendelsohn-Victor, MPH, and Marjorie C. McCullagh, PhD, RN, APHN-BC, COHN-S, FAAOHN, FAAN Abstract: OBJECTIVES: To evaluate whether a web-based educational intervention improved personal...
by CytoPrevent | Jan 25, 2019 | Studies
Christina C. Lawson, PhD, Candice Y. Johnson, PhD, Feiby L. Nassan, ScD, MBBCH, Thomas H. Connor, PhD, James M. Boiano, MS, Carissa M. Rocheleau, PhD, Jorge E. Chavarro, MD, ScD, and Janet W. Rich-Edwards, ScD Abstract: Purpose: The purpose of this study was to...
by CytoPrevent | Jun 8, 2018 | Studies
S. Ndaw, F. Denis, P. Marsan, A. Rémy, A. Robert Département Toxicologie et biométrologie, INRS Abstract: Utilisés dans le traitement des cancers, les médicaments cytotoxiques présentent une toxicité intrinsèque, du fait de leurs propriétés génotoxiques,...